These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18165205)

  • 1. Probrain natriuretic peptide for assessment of efficacy in heart failure treatment.
    Ozkara A; Turgut F; Selcoki Y; Karanfil A; Metin MR; Kanbay M; Tekin O; Akcay A
    Adv Ther; 2007; 24(6):1233-9. PubMed ID: 18165205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.
    Butler J; Anstrom KJ; Felker GM; Givertz MM; Kalogeropoulos AP; Konstam MA; Mann DL; Margulies KB; McNulty SE; Mentz RJ; Redfield MM; Tang WHW; Whellan DJ; Shah M; Desvigne-Nickens P; Hernandez AF; Braunwald E;
    JAMA Cardiol; 2017 Sep; 2(9):950-958. PubMed ID: 28700781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
    Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
    JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
    Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
    McKelvie RS; Komajda M; McMurray J; Zile M; Ptaszynska A; Donovan M; Carson P; Massie BM;
    J Card Fail; 2010 Feb; 16(2):128-34. PubMed ID: 20142024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NT-proBNP in monitoring treatment of patients with congestive heart failure.
    Al-Meslmani BM; Fahoum SK; Shamia MG
    Clin Lab; 2007; 53(1-2):35-9. PubMed ID: 17323823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
    J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study.
    Myhre PL; Vaduganathan M; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS
    Circ Heart Fail; 2020 Jan; 13(1):e006638. PubMed ID: 31957468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
    Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-terminal-probrain natriuretic peptide and echocardiography in patients with systolic heart failure.
    Al-Meslmani BM; Fahoum SK; Shamia MG
    Saudi Med J; 2005 Nov; 26(11):1695-8. PubMed ID: 16311650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison study on diagnostic and prognostic value of N-terminal probrain natriuretic peptide and atrium natriuretic peptide in chronic congestive heart failure].
    Dong H; Chen DQ; Wang Y; Li M
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1740-2. PubMed ID: 18819908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF.
    Sanders-van Wijk S; Muzzarelli S; Neuhaus M; Kiencke S; Maeder M; Estlinbaum W; Tobler D; Mayer K; Erne P; Pfisterer ME; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Aug; 15(8):910-8. PubMed ID: 23666681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort.
    Kobayashi M; Ferreira JP; Duarte K; Bresso E; Huttin O; Bozec E; Brunner La Rocca HP; Delles C; Clark AL; Edelmann F; González A; Heymans S; Pellicori P; Petutschnigg J; Verdonschot JAJ; Rossignol P; Cleland JGF; Zannad F; Girerd N;
    Eur J Heart Fail; 2024 May; 26(5):1231-1241. PubMed ID: 38528728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
    Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
    Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?).
    Stienen S; Salah K; Moons AH; Bakx AL; van Pol P; Kortz RAM; Ferreira JP; Marques I; Schroeder-Tanka JM; Keijer JT; Bayés-Genis A; Tijssen JGP; Pinto YM; Kok WE
    Circulation; 2018 Apr; 137(16):1671-1683. PubMed ID: 29242350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker?
    Li N; Li Y; Wang F; Jiang W; Huang J; Xu Z; Hua L; Hua C; Huang Y; Wu Y; Li F
    Clin Cardiol; 2007 Sep; 30(9):469-74. PubMed ID: 17803204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between NT-proBNP levels, functional capacity and stage in patients with heart failure.
    Karabulut A; Kaplan A; Aslan C; Iltumur K; Toprak G; Toprak N
    Acta Cardiol; 2005 Dec; 60(6):631-8. PubMed ID: 16385925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NT-ProBNP in acute heart failure: correlation with invasively measured hemodynamic parameters during recompensation.
    Knebel F; Schimke I; Pliet K; Schattke S; Martin S; Borges AC; Baumann G
    J Card Fail; 2005 Jun; 11(5 Suppl):S38-41. PubMed ID: 15948099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlations between serum intact parathyroid hormone (PTH) and N-terminal-probrain natriuretic peptide levels in elderly patients with chronic heart failure (CHF).
    Zhang S; Hu Y; Zhou L; Chen X; Wang Y; Wu J; He H; Gao Y
    Arch Gerontol Geriatr; 2015; 60(2):359-65. PubMed ID: 25466512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.